Literature DB >> 12625033

DU-127090 Solvay/H Lundbeck.

William Wolf1.   

Abstract

DU-127090 is a mixed dopamine antagonist/serotonin agonist in development by Solvay and H Lundbeck as a potential treatment for psychosis and schizophrenia, for which it is in phase II clinical trials. In August 2002, phase II trials were ongoing and Lundbeck expected to commence phase III trials in 2003 and file an NDA after 2004. DU-127090 is also under development for Parkinson's disease, for which it is in phase I clinical trials.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12625033

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN： 1472-4472


  9 in total

1.  In vivo occupancy of dopamine D2 receptors by antipsychotic drugs and novel compounds in the mouse striatum and olfactory tubercles.

Authors:  Marie-Bernadette Assié; Hélène Dominguez; Nathalie Consul-Denjean; Adrian Newman-Tancredi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-09-01       Impact factor: 3.000

2.  Discriminative stimulus properties of S32504, a novel D3/D2 receptor agonist and antiparkinson agent, in rats: attenuation by the antipsychotics, aripiprazole, bifeprunox, N-desmethylclozapine, and by selective antagonists at dopamine D2 but not D3 receptors.

Authors:  Mark J Millan; Loretta Iob; Jean-Louis Péglion; Anne Dekeyne
Journal:  Psychopharmacology (Berl)       Date:  2006-09-19       Impact factor: 4.530

3.  F15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. II. Activity in models of positive symptoms of schizophrenia.

Authors:  R Depoortère; L Bardin; A L Auclair; M S Kleven; E Prinssen; F Colpaert; B Vacher; A Newman-Tancredi
Journal:  Br J Pharmacol       Date:  2007-03-20       Impact factor: 8.739

4.  F15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. III. Activity in models of cognition and negative symptoms.

Authors:  R Depoortère; A L Auclair; L Bardin; L Bruins Slot; M S Kleven; F Colpaert; B Vacher; A Newman-Tancredi
Journal:  Br J Pharmacol       Date:  2007-03-20       Impact factor: 8.739

5.  Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study.

Authors:  Daniel E Casey; Earl E Sands; Jens Heisterberg; Hwa-Ming Yang
Journal:  Psychopharmacology (Berl)       Date:  2008-07-04       Impact factor: 4.530

6.  F15063, a potential antipsychotic with dopamine D(2)/D(3) antagonist, 5-HT(1A) agonist and D(4) partial agonist properties: (IV) duration of brain D2-like receptor occupancy and antipsychotic-like activity versus plasma concentration in mice.

Authors:  Marie-Bernadette Assié; Laurent Bardin; Agnès Auclair; Nathalie Consul-Denjean; François Sautel; Ronan Depoortère; Adrian Newman-Tancredi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-04-24       Impact factor: 3.195

7.  Postsynaptic 5-HT1A receptor stimulation increases motor activity in the 6-hydroxydopamine-lesioned rat: implications for treating Parkinson's disease.

Authors:  Laurence Mignon; William A Wolf
Journal:  Psychopharmacology (Berl)       Date:  2007-01-31       Impact factor: 4.415

8.  Putative antipsychotics with pronounced agonism at serotonin 5-HT1A and partial agonist activity at dopamine D2 receptors disrupt basal PPI of the startle reflex in rats.

Authors:  Agnès L Auclair; Alexandra Galinier; Joël Besnard; Adrian Newman-Tancredi; Ronan Depoortère
Journal:  Psychopharmacology (Berl)       Date:  2007-03-29       Impact factor: 4.415

Review 9.  Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism.

Authors:  Andrea de Bartolomeis; Carmine Tomasetti; Felice Iasevoli
Journal:  CNS Drugs       Date:  2015-09       Impact factor: 5.749
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.